The company views this development as a gateway to a massive commercial opportunity, noting that the global functional mushroom market is currently valued at over $38 billion. CEO Louis Herlands likens the breakthrough to the historical domestication of wild, toxic plants into common food staples, suggesting that removing the psychotropic component allows for broad access to previously restricted fungal compounds.
Beyond consumer supplements, the company plans to leverage this genetic innovation for pharmaceutical development. Myles Axton, a genetics researcher at LMI and former Chief Editor of Nature Genetics, emphasized that the process enables the production of over a dozen beneficial compounds that typically exist in trace amounts. By bypassing the need for highly restricted lab conditions, LMI intends to use synthetic biology to scale the production of these molecules. The firm is now actively seeking strategic partnerships with pharmaceutical and nutraceutical groups to bring these non-hallucinogenic candidates to market.
Comments (0)
No comments yet. Be the first!